ArticleWorld journal of surgical oncology2026
A quasi-bridge to surgery approach for stage IV obstructive colon cancer: extending the bridge-to-surgery concept to metastatic disease.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal management of stage IV colorectal cancer with malignant large bowel obstruction remains controversial. Self-expandable metallic stents are an established bridge to surgery in non-metastatic disease, but the role of primary tumor resection after stent placement in stage IV patients is unresolved. We propose and evaluate a "quasi-bridge to surgery" (Quasi-BTS) strategy in which stenting serves as a biological selection tool to identify patients who may benefit from delayed primary tumor resection.
methodsThis single-center retrospective cohort study analyzed consecutive stage IV obstructive colorectal cancer patients who underwent successful self-expandable metallic stent placement between January 2007 and December 2023. Patients were categorized into a Quasi-BTS group (delayed primary tumor resection), a palliative chemotherapy-only group, and palliative care-only group. Primary outcomes were overall survival, stent-related complications, and stoma-free survival.
resultsFifty-three patients were analyzed (Quasi-BTS, n = 16; palliative chemotherapy only, n = 22; palliative care only, n = 15). The Quasi-BTS group had zero overall stent-related complications versus 46.7% and 36.4% in the palliative care-only and palliative chemotherapy-only groups, respectively (P = 0.009); perforation alone was a non-significant trend (0% vs. 26.7% vs. 27.3%, P = 0.070). The laparoscopic surgery rate was 82%, the primary anastomosis rate was 92%, and bevacizumab was safely administered in all 6 patients who received it. Overall survival was significantly longer in the Quasi-BTS group than in either palliative group (log-rank all P < 0.001). After multivariable Cox adjustment for age, ASA, metastatic site, and targeted-therapy use, the Quasi-BTS group retained a markedly reduced hazard of death (adjusted HR 0.037, 95% CI 0.010-0.135). The mean interval from stent insertion to resection was 21.2 days in the resection-first subgroup.
conclusionsThe Quasi-BTS strategy may extend the bridge-to-surgery concept to metastatic colorectal cancer by repurposing stenting as a bridge for patient selection. Performing primary tumor resection within approximately three months of stent insertion was associated with the absence of stent-related complications in our cohort, appears to permit the subsequent use of anti-angiogenic targeted therapy without observed stent-related complications, and was associated with improved long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.